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ABSTRACT
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. We 
performed systematic database search and identified highly specific MED12 mutations 
in CLL patients. To study this further, we collected three independent sample series 
comprising over 700 CLL samples and screened MED12 exons 1 and 2 by direct 
sequencing. Mutations were identified at significant frequency in all three series with 
a combined mutation frequency of 5.2% (37/709). Positive mutation status was found 
to be associated with unmutated IGHV and ZAP70 expression, which are well-known 
poor prognosis markers in CLL. Our results recognize CLL as the first extrauterine 
cancer type where 5’terminus of MED12 is mutated at significant frequency. Functional 
analyses have shown that these mutations lead to dissociation of Cyclin C-CDK8/19 
from the core Mediator and to the loss of Mediator-associated CDK kinase activity. 
Additional studies on the role of MED12 mutation status as a putative prognostic factor 
as well as mutations’ exact tumorigenic mechanism in CLL are warranted.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is the most 
prevalent adult leukemia in Western societies. The disease 
is characterized by the accumulation of monoclonal CD5-, 
CD19-, and CD23-positive B cells in the blood and 
lymphoid tissues. The clinical course of patients with this 
disease is heterogeneous, ranging from highly indolent, 
which may never require therapy, to relatively aggressive, 
which may require therapy soon after diagnosis. CLL can 
be divided into two subclasses based on the occurrence of 
somatic hypermutation in the immunoglobulin heavy-chain 
variable (IGHV) genes. [1] The subclass with mutated 
IGHV genes (M-CLL) has an improved treatment-free and 
overall survival compared to the subclass with unmutated 
IGHV genes (U-CLL) [2, 3]. Currently, there is no curative 
drug therapy for CLL, but chemo-immunotherapy can 
significantly improve survival [4]. As the course of the 
disease is highly unpredictable, there is an urgent need to 
better elucidate the biology of CLL.
Recent large-scale sequencing studies have shown 
that the average number of somatic mutations in CLL is 
smaller than in solid tumors but comparable with other 
hematological neoplasms [5]. Only a few genes (e.g. 
TP53, NOTCH1, SF3B1, XPO1, BIRC3, MYD88) have 
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emerged as frequently mutated in CLL. In contrast, many 
other genes are recurrently mutated at lower frequencies 
(2–5%). There are also some CLL cases which do not have 
mutations in any known CLL driver gene. [Reviewed in 6] 
These observations emphasize the molecular heterogeneity 
of the disease and highlight the need for a comprehensive 
classification of CLL based on molecular characteristics.
Mediator is a multisubunit protein complex 
required for activator-dependent transcription of most 
protein coding genes. Mutations or altered expression 
of many Mediator subunits have been associated with 
various medical conditions ranging from cancer to 
neuropsychiatric illnesses. Mediator complex subunit 12 
(MED12), a 45 exon gene on Xq13.1, encodes a subunit 
of the Mediator’s kinase module. MED12 was first 
implicated in human tumorigenesis when highly specific 
exon 2 mutations were identified in as many as 70% of 
uterine leiomyomas [7]. Functional analyses indicated 
that these mutations disrupt the interaction between 
MED12 and Cyclin C-CDK8 and lead to a diminished 
Mediator-associated CDK kinase activity [8]. Recently, 
we identified mutations also in exon 1 and showed by 
expression profiling and functional analyses that they lead 
to similar unique global gene expression pattern and shared 
tumorigenic mechanisms as exon 2 mutations [8, 9].
Following the observation of specific MED12 
mutations in myomas, similar mutations have been 
searched for in several tumor types [e.g. 10–14]. 
Mutations have been detected at significant frequency in 
breast fibroadenomas (59%) and uterine leiomyosarcomas 
(7–20%), and rarely in extrauterine leiomyomas and 
leiomyosarcomas, endometrial polyps, and colorectal 
cancer. To analyze this more thoroughly, we performed 
a systematic database search utilizing the Catalogue 
of Somatic Mutations in Cancer (COSMIC) [15]. 
Interestingly, the search revealed five MED12 mutations 
in CLL. All these mutations were in exon 1 or 2: three 
affected the mutation hotspots observed in uterine 
leiomyomas (codons L36 and G44), the fourth was a 
missense change altering the last amino acid of exon 1 
(E33K), and the fifth resulted in A59P substitution. These 
data have been retrieved from various recent exome and 
whole genome sequencing studies, and no mutations 
in other parts of the gene have been identified. This 
surprising database finding prompted us to systematically 
study the contribution of MED12 in CLL.
RESULTS
Altogether 746 samples from three independent 
sample series were included in the study. MED12 exons 
1 and 2 were successfully sequenced in 709 samples 
(709/746, 95%). This analysis revealed mutations in 
37 samples (37/709; 5.2% Supplementary Table 2; two 
samples had two mutations). Mutations were recurrently 
identified in each sample series with frequencies of 7.7% 
(20/260; CRC samples), 3.6% (10/274; Sample Bank 
samples), and 4.0% (7/175; Finnish samples). There is 
no obvious bias in the collection or characteristics of the 
sample series, which could explain the slightly higher 
mutation frequency in the CRC series.
All the observed mutations were either missense 
mutations affecting highly conserved amino acids or small 
insertions or deletions resulting in an in-frame transcript 
(Figure 1). The most commonly mutated sites were codons 
G44 (11/39; 28%, including 9 missense mutations and 2 
deletions) and E33 (9/39; 23%, all missense mutations). 
Many of the remaining mutations affected the previously 
reported mutation hotspots (c.100-8T, L36, and Q43). Two 
variants with unknown significance, a substitution c.1–28G 
> T in the UTR and a silent p.R16R in exon 1, were also 
observed. As their effect on protein function is unclear, they 
were excluded from the mutation frequency calculations 
and the association analyses. Detailed information on the 
observed mutations and the mutation positive samples are 
presented in Supplementary Table 2.
Association analyses were performed based on the 
molecular and clinical data available from the patients in 
the CRC series. Interestingly, MED12 mutations were 
associated with markers of poor prognosis: unmutated IGHV 
[2, 3] (p = 6.8x10−4), ZAP-70 protein positivity [16] (≥ 20% 
expression) (p = 7.1x10−4), and unmethylated (< 20%) 
ZAP-70 [17] (p = 5.5x10−4) (Table 1). More specifically, all 
20 patients with the MED12 mutation had the established 
poor prognostic unmutated IGHV disease status, and all 19 
who were measured for similar adverse prognostic ZAP-70 
methylation were unmethylated. No differences in time to 
treatment or overall survival were, however, detected.
Figure 1: Schematic presentation of MED12 exon 1 and exon 2 mutations in CLL identified in this study. Amino acids and 
codon numbers are shown below the DNA sequence. Arrows indicate substitutions and grey bars insertion/deletion mutations, respectively. 
Numbers above arrows indicate how many times each mutation was detected. Mutation hotspot codons observed in uterine leiomyomas 
are marked with red. Amino acids are color-coded according to their side-chain pKas and charge at physiological pH 7.4. Red = negatively 
charged; green = hydrophobic; yellow = small non-polar, magenta = polar, blue = positively charged.
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DISCUSSION
Highly specific MED12 mutations were first 
observed in benign uterine leiomyomas [7]. Subsequent 
mutation analyses have revealed recurrent mutations also 
in breast fibroadenomas and uterine leiomyosarcomas 
[11–14]. Here, prompted by the systematic analysis 
of somatic mutation database, we have collected three 
independent sample series totaling a comprehensive 
series of more than 700 CLL samples. Mutation 
screening revealed recurrent mutations in all three series 
with a combined mutation frequency of 5.2% (37/709). 
These results indicate that in addition to solid hormone 
dependent female tumors, MED12 mutations are involved 
also in CLL pathogenesis. Significant mutation frequency 
also implies that MED12 should be recognized as an 
important cancer gene in CLL.
As in uterine leiomyomas, leiomyosarcomas, and 
breast fibroadenomas, all MED12 mutations in CLL 
are missense changes or small in-frame insertions and 
deletions. The most commonly affected mutation hotspot 
in all tumor types is codon G44. Despite these similarities 
in mutation profiles, also an interesting difference was 
observed. A novel MED12 mutation hotspot was identified 
in CLL as mutations affecting the last amino acid of exon 
1, E33, were seen nine times (Figure 1 and Supplementary 
Table 2). Similar mutations have previously been observed 
twice in CLL [18], once in bladder carcinoma [15], and 
twice in colorectal cancer [15, 19]. No missense mutations 
at E33 have been reported in uterine leiomyomas, although 
a few deletions removing the site have been detected [9]. 
Altogether 12 of the 39 mutations observed in this study 
were in exon 1 (31%) and 27 (69%) in exon 2. The location 
of mutations in CLL (current study and COSMIC database) 
is statistically different from the location of mutations in 
uterine leiomyomas, where nearly all reported mutations 
(173/178; 97%) have been in exon 2 (p = 6.0x10−7) [7, 
9, 20]. Our recent data shows that the Cyclin C-CDK8 
binding domain of MED12 consists of its 100 N-terminal 
amino acids, largely encoded by exons 1 and 2 [8]. Gene 
expression profiling and functional analyses indicate that 
mutations within these exons lead to similar expression 
Table 1: Demographic and molecular features by MED12 mutation status in CLL Research Consortium sample series. 
MED12 mutations are associated with markers of poor prognosis in CLL: unmutated IGHV, ZAP-70 protein positivity, and 
unmethylated ZAP-70.
CLL Marker Data MED12 Not Mutated (n = 240) MED12 Mutated (n = 20) P
Age
 Median 55 56 0.55
 Range 26–82 44–72
Sex
 Male 169 (70%) 16 (80%) 0.45
 Female 71 (30%) 4 (20%)
IGHV
 Mutated 79 (33%) 0 (0%) < 0.001
 Unmutated (≥ 98%*) 161 (67%) 20 (100%)
CD38
 Negative 115 (48%) 5 (25%) 0.06
 Positive (≥ 20%) 125 (52%) 15 (75%)
ZAP-70
 Negative 117 (49%) 2 (10%) < 0.001
 Positive (≥ 20%) 123 (51%) 18 (90%)
ZAP-70 Methylation
 Methylated (≥ 20%) 84 (35%) 0 (0%) < 0.001
 UnMethylated (< 20%) 153 (65%) 19 (100%)
 Unknown 3 1
*Sequences showing 98% or greater homology to the corresponding germ-line IGHV sequence were considered unmutated.
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profiles and shared tumorigenic mechanism, involving 
diminished Mediator-associated kinase activity [8, 9]. 
Whether the observation of different exon1 and 2 mutation 
ratios reflects true tissue specific functional relevance will 
need to be determined with further research.
Extensive molecular and clinical data were available 
from one US sample series. Interestingly, association 
analyses showed significant association between 
MED12 mutations and unmutated IGHV status, ZAP70 
expression, and unmethylated ZAP70, which are well-
known poor prognosis markers in CLL [2, 3, 16, 17]. 
Possible associations with time to treatment and overall 
survival were also analyzed, but no differences were 
observed. The role of MED12 mutational status as a 
putative prognostic factor will need to be studied further, 
where our data support investigations in a larger series of 
high-risk patients adequately powered to detect moderate 
differences in clinical outcome.
A few MED12 mutations in CLL have been identified 
in recent large-scale sequencing studies [18, 21–24]. As 
these have been rare mutation positive cases in independent 
studies, the significant MED12 mutation frequency in 
CLL has not been recognized prior to this study. Also our 
literature search of PubMed with the words “MED12” and 
“leukemia” did not produce any results. This highlights 
the utility of comprehensive mutation databases, which 
facilitate identification of true cancer genes which are 
mutated recurrently but at moderate frequency.
Our results recognize CLL as the first extrauterine 
cancer type where the 5’ terminus of MED12 is mutated at 
significant frequency. We also show that these mutations 
are associated with poor prognosis markers in CLL. 
Identification of such specific mutations in highly different 
tumor types -benign uterine leiomyomas and breast 
fibroadenomas, and a malignant chronic leukemia- is both 
puzzling and intriguing. While the immediate effects of 
the mutations on the interactions and kinase activity of the 
Mediator complex may be similar, the downstream effects 
on transcription may differ in various tissue types. Overall, 
the results from this study suggest that MED12 plays a 
role in the pathogenesis of CLL. Further investigations of 
MED12’s function in CLL are warranted.
METHODS
Three independent sample series from the United 
States and Finland comprising altogether 746 samples were 
collected for the study. The first US series consisted of 
278 samples obtained from the CLL Research Consortium 
(CRC) and the second included 292 samples from The 
Ohio State University’s Human Genetics Sample Bank. 
The Finnish CLL series, consisting of 176 samples, was 
obtained from the Helsinki University Central Hospital 
clinical sample collection. Samples were collected either 
after signed informed consent (living patients) or with 
authorization from the Ethics Committee of the Helsinki 
University Central Hospital (deceased Finnish patients). 
The study was approved by the Institutional Review Board 
of each participating CRC site, The Ohio State University, 
and the Ethics Review Board of the Hospital District of 
Helsinki and Uusimaa, Helsinki, Finland.
All MED12 mutations observed in exome or whole 
genome sequencing studies on CLL have resided in exons 
1 and 2. Even though some mutations in other exons 
might be detectable by targeted sequencing with higher 
depth of coverage, results from these studies suggest that 
similarly to uterine leiomyomas, MED12 mutations in 
CLL are restricted to exons 1 and 2. In this study, mutation 
screening of exons 1 and 2 was done by direct sequencing 
using previously described primers [9, 12]. Samples were 
sequenced with Applied Biosystems 3730 DNA Analyzer 
(Life Technologies, Thermo Fischer Scientific Waltham, 
MA, USA) and analyzed manually and with Mutation 
Surveyor (Softgenetics, State College, PA, USA) or 
Lasergene SeqMan Pro (DNASTAR, Madison, WI, USA) 
softwares. See Supplemental Data for more details on the 
sample series and methods.
Molecular and clinical data were available from 
patients in the CRC series. Associations between the 
MED12 mutations and various demographic and molecular 
characteristics were analyzed using Fisher’s exact and 
Wilcoxon rank sum tests for categorical and continuous 
variables, respectively.
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